CTLA-4-containing schedules require heightened caution: baseline stool history, early GI input, and a “treat-early” steroid stance for diarrhea/abdominal pain to prevent complicated colitis, the dominant cause of ipilimumab-related deaths in prior reports [14,15,28]. This evidence concerns the gene CTLA4 and colitis.